AVTX vs NEM · P/E 0.0, $51.5M cap vs P/E 14, rev $13.43B
Avalo Therapeutics Inc (AVTX) versus Newmont Goldcorp Corp (NEM) — a side-by-side from cached financials, not a winner call.
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
Newmont Goldcorp Corp (NEM) is a gold company listed on NYSE.
Latest reported AVTX revenue for 2025-09-30 was $0. Net income was -$30.6M. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.
Latest reported NEM revenue for 2026-06-30 was $13.43B. Net income was $5.46B. Revenue was up 83.7% from 2026-03-31 to 2026-06-30. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
AVTX currently screens at market cap $51.5M and trailing P/E 0.0. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
Not investment advice. Open the AVTX and NEM stock pages for the full models.
Not investment advice.